Which has stronger earnings and valuation, KRYS or ONC?

BeOne Medicines has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 27.53 $204.83M $7.48 48.59 BeOne Medicines $5.34B 6.24 $286.93M $4.47 68.00

Is MRNA or KRYS more profitable?

Krystal Biotech has a net margin of 53.92% compared to Moderna's net margin of -143.55%. Krystal Biotech's return on equity of 19.25% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Krystal Biotech 53.92% 19.25% 17.62%

Which has higher earnings & valuation, ROIV or KRYS?

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 3,005.09 -$299.77M -$0.60 N/A Krystal Biotech $389.13M 27.53 $204.83M $7.48 48.59

Krystal Biotech (KRYS) Competitors

$363.44 -2.37 (-0.65%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$362.50 -0.94 (-0.26%)

As of 07/13/2026 07:57 PM Eastern

Compare

KRYS vs. RVMD, TEVA, ONC, MRNA, and ROIV

Should you buy Krystal Biotech stock or one of its competitors? MarketBeat compares Krystal Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Krystal Biotech include Revolution Medicines (RVMD), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Moderna (MRNA), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.

How does Krystal Biotech compare to Revolution Medicines?

Krystal Biotech (NASDAQ:KRYS) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	27.53	$204.83M	$7.48	48.59
Revolution Medicines	$11.58M	3,377.18	-$1.13B	-$7.07	N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Revolution Medicines had 10 more articles in the media than Krystal Biotech. MarketBeat recorded 11 mentions for Revolution Medicines and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.87 beat Revolution Medicines' score of 0.63 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Krystal Biotech	Very Positive
Revolution Medicines	Positive

Krystal Biotech presently has a consensus price target of $352.00, indicating a potential downside of 3.15%. Revolution Medicines has a consensus price target of $144.00, indicating a potential downside of 21.72%. Given Krystal Biotech's higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Krystal Biotech has a net margin of 53.92% compared to Revolution Medicines' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Revolution Medicines	N/A	-83.22%	-59.06%

Summary

Krystal Biotech beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Teva Pharmaceutical Industries?

Krystal Biotech (NASDAQ:KRYS) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Teva Pharmaceutical Industries has higher revenue and earnings than Krystal Biotech. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	27.53	$204.83M	$7.48	48.59
Teva Pharmaceutical Industries	$17.26B	2.14	$1.41B	$1.33	24.17

In the previous week, Teva Pharmaceutical Industries had 20 more articles in the media than Krystal Biotech. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.87 beat Teva Pharmaceutical Industries' score of 1.13 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Krystal Biotech	Very Positive
Teva Pharmaceutical Industries	Positive

Krystal Biotech has a net margin of 53.92% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Krystal Biotech currently has a consensus target price of $352.00, indicating a potential downside of 3.15%. Teva Pharmaceutical Industries has a consensus target price of $41.78, indicating a potential upside of 29.94%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Summary

Krystal Biotech beats Teva Pharmaceutical Industries on 10 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to BeOne Medicines?

Krystal Biotech (NASDAQ:KRYS) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Krystal Biotech has a net margin of 53.92% compared to BeOne Medicines' net margin of 8.94%. Krystal Biotech's return on equity of 19.25% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
BeOne Medicines	8.94%	12.06%	6.69%

Krystal Biotech has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

Krystal Biotech currently has a consensus target price of $352.00, indicating a potential downside of 3.15%. BeOne Medicines has a consensus target price of $391.38, indicating a potential upside of 28.76%. Given BeOne Medicines' higher possible upside, analysts plainly believe BeOne Medicines is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

BeOne Medicines has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	27.53	$204.83M	$7.48	48.59
BeOne Medicines	$5.34B	6.24	$286.93M	$4.47	68.00

In the previous week, BeOne Medicines had 7 more articles in the media than Krystal Biotech. MarketBeat recorded 8 mentions for BeOne Medicines and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.87 beat BeOne Medicines' score of 0.77 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Krystal Biotech	Very Positive
BeOne Medicines	Positive

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Krystal Biotech beats BeOne Medicines on 10 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Moderna?

Moderna (NASDAQ:MRNA) and Krystal Biotech (NASDAQ:KRYS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Krystal Biotech has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	13.68	-$2.82B	-$8.15	N/A
Krystal Biotech	$389.13M	27.53	$204.83M	$7.48	48.59

Moderna has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Moderna currently has a consensus target price of $38.27, indicating a potential downside of 42.89%. Krystal Biotech has a consensus target price of $352.00, indicating a potential downside of 3.15%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Moderna had 23 more articles in the media than Krystal Biotech. MarketBeat recorded 24 mentions for Moderna and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.87 beat Moderna's score of 0.82 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Moderna	Positive
Krystal Biotech	Very Positive

75.3% of Moderna shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Krystal Biotech has a net margin of 53.92% compared to Moderna's net margin of -143.55%. Krystal Biotech's return on equity of 19.25% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Krystal Biotech	53.92%	19.25%	17.62%

Summary

Krystal Biotech beats Moderna on 13 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

In the previous week, Roivant Sciences had 4 more articles in the media than Krystal Biotech. MarketBeat recorded 5 mentions for Roivant Sciences and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.87 beat Roivant Sciences' score of 0.70 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Roivant Sciences	Positive
Krystal Biotech	Very Positive

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A
Krystal Biotech	$389.13M	27.53	$204.83M	$7.48	48.59

Roivant Sciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to Roivant Sciences' net margin of -3,629.19%. Krystal Biotech's return on equity of 19.25% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Krystal Biotech	53.92%	19.25%	17.62%

Roivant Sciences currently has a consensus price target of $33.59, indicating a potential downside of 2.66%. Krystal Biotech has a consensus price target of $352.00, indicating a potential downside of 3.15%. Given Roivant Sciences' higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Krystal Biotech beats Roivant Sciences on 11 of the 15 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export

Metric	Krystal Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.78B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	48.59	20.85	27.15	24.26
Price / Sales	27.53	314.01	587.92	117.88
Price / Cash	50.18	61.98	29.22	49.36
Price / Book	8.64	8.49	10.75	6.29
Net Income	$204.83M	$23.83M	$3.58B	$330.66M
7 Day Performance	-1.40%	-3.56%	-2.07%	-1.32%
1 Month Performance	14.30%	6.31%	3.31%	-0.64%
1 Year Performance	141.63%	48.30%	26.35%	19.08%

Krystal Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	2.6246 of 5 stars	$363.44 -0.6%	$352.00 -3.1%	+145.3%	$10.78B	$389.13M	48.59	210	Positive News Analyst Forecast
RVMD Revolution Medicines	1.9594 of 5 stars	$189.99 +0.4%	$142.33 -25.1%	+383.8%	$40.23B	$11.58M	N/A	250	Gap Down
TEVA Teva Pharmaceutical Industries	4.8031 of 5 stars	$35.29 +1.9%	$41.78 +18.4%	+96.2%	$39.83B	$17.26B	26.53	33,950	Positive News Analyst Downgrade
ONC BeOne Medicines	4.6788 of 5 stars	$309.46 +4.0%	$390.00 +26.0%	+21.4%	$32.66B	$5.34B	66.59	12,000
MRNA Moderna	1.8577 of 5 stars	$81.80 +2.6%	$37.13 -54.6%	+99.2%	$31.65B	$1.94B	N/A	4,700	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Krystal Biotech compare to Revolution Medicines?

Summary

How does Krystal Biotech compare to Teva Pharmaceutical Industries?

Summary

How does Krystal Biotech compare to BeOne Medicines?

Summary

How does Krystal Biotech compare to Moderna?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. RVMD, TEVA, ONC, MRNA, and ROIV

How does Krystal Biotech compare to Revolution Medicines?

Which has more volatility and risk, KRYS or RVMD?

Which has stronger valuation & earnings, KRYS or RVMD?

Do insiders & institutionals hold more shares of KRYS or RVMD?

Does the media refer more to KRYS or RVMD?

Do analysts prefer KRYS or RVMD?

Is KRYS or RVMD more profitable?

Summary

How does Krystal Biotech compare to Teva Pharmaceutical Industries?

Which has stronger earnings and valuation, KRYS or TEVA?

Does the media favor KRYS or TEVA?

Is KRYS or TEVA more profitable?

Do analysts recommend KRYS or TEVA?

Do institutionals and insiders believe in KRYS or TEVA?

Which has more risk and volatility, KRYS or TEVA?

Summary

How does Krystal Biotech compare to BeOne Medicines?

Is KRYS or ONC more profitable?

Which has more risk and volatility, KRYS or ONC?

Do analysts recommend KRYS or ONC?

Which has stronger earnings and valuation, KRYS or ONC?

Does the media favor KRYS or ONC?

Do institutionals and insiders believe in KRYS or ONC?

Summary

How does Krystal Biotech compare to Moderna?

Which has stronger valuation & earnings, MRNA or KRYS?

Which has more volatility and risk, MRNA or KRYS?

Do analysts rate MRNA or KRYS?

Does the media refer more to MRNA or KRYS?

Do institutionals and insiders hold more shares of MRNA or KRYS?

Is MRNA or KRYS more profitable?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Does the media prefer ROIV or KRYS?

Which has higher earnings & valuation, ROIV or KRYS?

Which has more risk and volatility, ROIV or KRYS?

Is ROIV or KRYS more profitable?

Do analysts recommend ROIV or KRYS?

Do institutionals & insiders believe in ROIV or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools